According to a recent LinkedIn post from Truveta, the company’s Truveta Research unit is referenced in a Reuters article examining a rapid rise in the use of estrogen patches and associated supply constraints. The post indicates that Truveta’s analysis identified a 26% increase in estrogen patch use following recent FDA actions, and a 184% increase since 2023.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests these patterns reflect growing demand for hormone replacement therapy and illustrate how quickly changes in regulatory guidance may influence real-world care. For investors, this visibility into utilization trends could underscore the potential value of Truveta’s real-world data platform for life sciences and healthcare stakeholders.
By highlighting its role in quantifying therapy adoption and identifying emerging access gaps, the post implies that Truveta may be strengthening its positioning as a data partner for pharmaceutical and healthcare organizations. Such recognition in mainstream media outlets like Reuters could enhance brand credibility, potentially supporting future commercial relationships and revenue opportunities linked to data analytics and evidence generation.